Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.
about
Endogenous opiates and behavior: 2006The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.A double blind, within subject comparison of spontaneous opioid withdrawal from buprenorphine versus morphineThe World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence.Preliminary buprenorphine sublingual tablet pharmacokinetic data in plasma, oral fluid, and sweat during treatment of opioid-dependent pregnant womenBuprenorphine for opioid dependenceHealth-related quality of life changes associated with buprenorphine treatment for opioid dependence.Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.Buprenorphine implant for opioid addictionFunctionalization of the 6,14-bridge of the orvinols. Part 3: preparation and pharmacological evaluation of 18- and 19-hydroxyl substituted orvinols.Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.Retention in methadone and buprenorphine treatment among African Americans.Probuphine® (buprenorphine implant): a promising candidate in opioid dependence.Buprenorphine and buprenorphine/naloxone soluble-film for treatment of opioid dependence.Buprenorphine-naloxone buccal soluble film for the treatment of opioid dependence: current update.A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration.The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations.Medication-assisted treatment for opioid addiction: methadone and buprenorphine.
P2860
Q28752585-33E10AD8-09B2-4E88-8DFA-DB1C356495CBQ30490602-13FD36D7-3EBC-45CF-A5FD-A446241D7E7FQ30570686-31AC7076-6973-45EA-84A6-31368B246534Q33870389-AB526EBF-AE27-4782-8B4B-0A0AD9BA7194Q34000757-4E106E67-C745-4240-ABBD-0946C5CF5DECQ34119459-261D5B8E-B29B-4A1D-AE50-2A3C8A0A6C13Q34129263-2ECEDAC3-714E-420E-83E8-2A0859716A93Q34615753-0C712599-7D18-4825-A703-55FFA3B2FEB3Q34820000-73F59068-2264-4434-BCE0-52E495347640Q36156117-83B4CB15-E7A3-473D-A327-B3C15E6EC647Q36394429-79837A06-9428-49FC-9894-719C5968C5A0Q37022122-E2857866-C124-4F29-A59C-4021CEF7A7ACQ37705253-FEA136C8-889D-403E-BF21-51E977F7D52DQ38046650-6848BB13-6178-4714-A9E8-EFD82914ED24Q38243268-0440BDCB-3C32-427C-8122-42366DCB0986Q38661092-2F4D8E57-B4AF-48C1-A5BF-3C3F31D41BA4Q40966093-2AD453F5-9880-4A81-ABEC-73BDE182F268Q41868954-EC76D36A-10E1-48AE-B52F-ED7D24CE2820
P2860
Pharmacokinetics, bioavailability and opioid effects of liquid versus tablet buprenorphine.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Pharmacokinetics, bioavailabil ...... d versus tablet buprenorphine.
@ast
Pharmacokinetics, bioavailabil ...... d versus tablet buprenorphine.
@en
Pharmacokinetics, bioavailabil ...... d versus tablet buprenorphine.
@nl
type
label
Pharmacokinetics, bioavailabil ...... d versus tablet buprenorphine.
@ast
Pharmacokinetics, bioavailabil ...... d versus tablet buprenorphine.
@en
Pharmacokinetics, bioavailabil ...... d versus tablet buprenorphine.
@nl
prefLabel
Pharmacokinetics, bioavailabil ...... d versus tablet buprenorphine.
@ast
Pharmacokinetics, bioavailabil ...... d versus tablet buprenorphine.
@en
Pharmacokinetics, bioavailabil ...... d versus tablet buprenorphine.
@nl
P2093
P1476
Pharmacokinetics, bioavailabil ...... d versus tablet buprenorphine.
@en
P2093
David Moody
Nora Chiang
Peggy Compton
Walter Ling
P356
10.1016/J.DRUGALCDEP.2005.08.005
P577
2005-09-06T00:00:00Z